These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38655266)

  • 1. SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma.
    Huang Z; Chen X; Wang Y; Yuan J; Li J; Hang W; Meng H
    Front Immunol; 2024; 15():1372215. PubMed ID: 38655266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bulk RNA-seq and scRNA-seq reveal SLC7A11, a key regulatory molecule of ferroptosis, is a prognostic-related biomarker and highly related to the immune system in lung adenocarcinoma.
    Wu X; Wang S; Chen K
    Medicine (Baltimore); 2023 Sep; 102(37):e34876. PubMed ID: 37713821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comprehensive Prognostic and Immune Analysis of Ferroptosis-Related Genes Identifies SLC7A11 as a Novel Prognostic Biomarker in Lung Adenocarcinoma.
    Qian L; Wang F; Lu SM; Miao HJ; He X; Feng J; Huang H; Shi RF; Zhang JG
    J Immunol Res; 2022; 2022():1951620. PubMed ID: 35509981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma.
    Koh YW; Han JH; Haam S; Lee HW
    Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
    Sui P; Liu X; Zhong C; Sha Z
    Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti-PD-1/PD-L1 immunotherapy in lung adenocarcinoma.
    Zhou M; Zhang X; Li T; Chen Y
    J Clin Lab Anal; 2021 Dec; 35(12):e24086. PubMed ID: 34752672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
    Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
    PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
    Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
    BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The splicing factor SF3B1 confers ferroptosis resistance and promotes lung adenocarcinoma progression via upregulation of SLC7A11.
    Guo Y; Wang X; Du Y; Zhao Y; Gao L; Hao Y; Lv D; Feng X; Zhai Y; Zou B; Han J; Xu E; Yang Y; Yang B; Xi Y; Zhang L
    Cancer Gene Ther; 2024 Oct; 31(10):1498-1510. PubMed ID: 39127833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
    Yang P; He S; Ye L; Weng H
    Int Arch Allergy Immunol; 2024; 185(9):910-920. PubMed ID: 38781935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
    Zhou F; Wang X; Liu F; Meng Q; Yu Y
    Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of KLRB1 is associated with increased cell growth, metastasis, poor prognosis, as well as a dysfunctional immune microenvironment in LUAD.
    Chen JL; Wu CY; Luo XY; Wang XY; Wang FM; Huang X; Yuan W; Guo Q
    Sci Rep; 2024 May; 14(1):11782. PubMed ID: 38782996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXA1/UBE2T Inhibits CD8
    Pu J; Zhang D; Wang B; Zhu P; Yang W; Wang K; Yang Z; Song Q
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):134. PubMed ID: 38682180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circ_BBS9 as an early diagnostic biomarker for lung adenocarcinoma: direct interaction with IFIT3 in the modulation of tumor immune microenvironment.
    Peng D; Liang M; Li L; Yang H; Fang D; Chen L; Guan B
    Front Immunol; 2024; 15():1344954. PubMed ID: 39139574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsa_circ_0070440 promotes lung adenocarcinoma progression by SLC7A11-mediated-ferroptosis.
    Zhao Y; Cui Q; Shen J; Shen W; Weng Y
    Histol Histopathol; 2023 Dec; 38(12):1429-1441. PubMed ID: 36852950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
    Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
    Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression.
    Lu Y; Wu F; Cao Q; Sun Y; Huang M; Xiao J; Zhou B; Zhang L
    Oncogene; 2022 Jan; 41(5):704-717. PubMed ID: 34839353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
    Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
    Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.